rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2017-138-150

rsp-2355

Research Article

МЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙ

INTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASES

Рекомендации EULAR по диагностике и лечению раннего артрита: 2016

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS

Насонов

Е. Л.

Nasonov

E. L.

nasonov@irramn.ru

1 ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой», Москва 2 ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, кафедра ревматологии Института профессионального образования, МоскваРоссия1 V.A. Nasonova Research Institute of Rheumatology, Moscow, 2 Department of Rheumatology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, MoscowRussian Federation

2017

24042017

552138150

2017

Насонов Е.Л.

Nasonov E.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/2355

Ранний артрит, который часто определяют как недифференцированный артрит (НДА), может быть ран- ней стадией ревматоидного артрита (РА), первым проявлением широкого спектра ревматических заболеваний и в течение длительного времени оставаться недифференцированным или завершаться спонтанно. В статье обсуждаются новые рекомендации Европейской антиревматической лиги (EULAR) по ведению пациентов с ранним артритом, в которых отражены достижения за последние 10 лет, связанные с новыми методами диагностики и лечения раннего артрита, в первую очередь – как кардинального симптомокомплекса РА. Рекомендации включают три общих принципа и 12 рекомендаций, касающихся диагностики и лечения раннего артрита. Особое внимание уделяется необходимости раннего назначения метотрексата, монотерапия которым является «золотым стандартом» в фармакотерапии РА. В заключение обсуждаются новые данные, касающиеся возможности профилактики РА в группе пациентов с АЦЦП-позитивными артралгиями.

Early arthritis, which is frequently defined as undifferentiated arthritis, can be an early stage of rheumatoid arthritis (RA), the first manifestation of a wide spectrum of rheumatic diseases and remain undifferentiated for a long time or end spontaneously. The article discusses new European League Against Rheumatism (EULAR) guidelines for the management of patients with early arthritis, which reflect the past decade's advances in new methods for the diagnosis and treatment of early arthritis primarily as a cardinal RA symptom complex. The guidelines include three general principles and 12 recommendations for the diagnosis and treatment of early arthritis. Special attention is given to the need for early use of methotrexate, monotherapy with the latter is the gold standard for the pharmacotherapy of RA. In conclusion, the paper discusses new evidence for the possibilities of preventing RA in a group of anti-cyclic citrullinated peptide antibodies positive patients with arthralgias.

ранний артритревматоидный артритметотрексатантитела к циклическому цитруллини- рованному пептиду

early arthritisrheumatoid arthritismethotrexateanti-cyclic citrullinated peptide antibodies

References1

Machado P, Castrejon I, Katchamart W, et al. Multinational evidence-based recommendations on how to investigate and followup undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2011;70(1):15-24. doi: 10.1136/ard.2010.130625

Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34- 45. doi: 10.1136/ard.2005.044354

Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3-15. doi: 10.1136/annrheumdis-2015-207524

Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75. doi: 10.1136/ard.2009.126532

Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509. doi: 10.1136/annrheumdis-2013-204573

Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Mar 6. pii: annrheumdis-2016- 210715. doi: 10.1136/annrheumdis-2016-210715

Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно- практическая ревматология. 2013;51(6):609-22 [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and disputable problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(6):609-22 (In Russ.)]. doi: 10.14412/1995-4484-2013-609-22

Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2016 Dec 15. pii: annrheumdis-2016-210602. doi: 10.1136/annrheumdis-2016-210602

Van der Linden MPM, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62:3537-46. doi: 10.1002/art.27692

Feldman DE, Bernatsky S, Houde M, et al. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? Rheumatology. 2013;52:452-9. doi: 10.1093/rheumatology/kes231

Bruschi E, Casu C, Filippini D, et al. Improving diagnosis of early inflammatory arthritis: results of a novel triage system. Clin Exp Rheumatol. 2013;31:606-9.

Tavares R, Wells GA, Bykerk VP, et al. Validation of a self-administered inflammatory arthritis detection tool for rheumatology triage. J Rheumatol. 2013;40:417-24. doi: 10.3899/jrheum.120096

Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002;61:290-7. doi: 10.1136/ard.61.4.290

Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic literature informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open. BMJ. 2017 Jan;3(1):e000406. doi: 10.1136/rmdopen-2016-000406

Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72:804-14. doi: 10.1136/annrheumdis-2012-203158

Mangnus L, Schoones JW, van der Helm-van Mil AHM. What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data. RMD Open. 2015;1:e000005. doi: 10.1136/rmdopen-2014-000005

Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol. 2005;32:231-8.

Bizzaro N, Bartoloni E, Morozzi G, et al. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther. 2013;15:R16. doi: 10.1186/ar4148

Van Aken J, van Dongen H, le Cessie S, et al. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis. 2006;65:20-5. doi: 10.1136/ard.2005.038471

Binard A, Alassane S, Devauchelle-Pensec V, et al. Outcome of early monoarthritis: a followup study. J Rheumatol. 2007;34:2351-7.

Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-8. doi: 10.1136/ard.2010.138461

Mouterde G, Lukas C, Logeart I, et al. Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis. Ann Rheum Dis. 2011;70:1251-6. doi: 10.1136/ard.2010.144402

Van den Broek M, Dirven L, Klarenbeek NB, et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis. 2012;71:245-8. doi: 10.1136/annrheumdis-2011-200379

Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis. 2010;69:1789-95. doi: 10.1136/ard.2009.125534

Degboe Y, Constantin A, Nigon D, et al. Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort. RMD Open. 2015;1:e000180. doi: 10.1136/rmdopen-2015-000180

Akdemir G, Verheul MK, Heimans L, et al. Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. RMD Open 2016;2:e000172. doi: 10.1136/rmdopen-2015-000172

Kudo-Tanaka E, Ohshima S, Ishii M, et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol. 2007;26:1627-33. doi: 10.1007/s10067-007-0558-5

Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol. 2007;26:499-504. doi: 10.1007/s10067-006-0309-z

Emad Y, Shehata M, Ragab Y, et al. Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis. Mod Rheumatol. 2010;20:358-65. doi: 10.3109/s10165- 010-0286-6

Chen D, Li H, Liang L, et al. Clinical features and independent predictors in the further development of rheumatoid arthritis in undifferentiated arthritis. Rheumatol Int. 2013;33:2827-32. doi: 10.1007/s00296-013-2799-8

Moghimi J, Ghorbani R, Hasani F, et al. Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis. Rheumatol Int. 2013;33:601-5. doi: 10.1007/s00296-012-2414-4

Funovits J, Aletaha D, Bykerk V, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis. 2010;69:1589-95. doi: 10.1136/ard.2010.130310

Boire G, Cossette P, de Brum-Fernandes AJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther. 2005;7:R592-603. doi: 10.1186/ar1719

Van der Linden MPM, van der Woude D, Ioan-Facsinay A, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum. 2009;60:2232-41. doi: 10.1002/art.24716

Pratt AG, Charles PJ, Chowdhury M, et al. Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Ann Rheum Dis. 2011;70:2056-8. doi: 10.1136/ard.2010.148197

De Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes – what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50:93-100. doi: 10.1093/rheumatology/keq230

Ursum J, Nielen MMJ, van Schaardenburg D, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther. 2008;10:R12. doi: 10.1186/ar2362

Damjanovska L, Thabet MM, Levarth EWN, et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis. 2010;69:730-2. doi: 10.1136/ard.2009.108456

Nicaise-Roland P, Nogueira L, Demattei C, et al. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and antiCCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis. 2013;72:357-62. doi: 10.1136/annrheumdis-2011-201056

Regueiro C, Peiteado D, Nuno L, et al. Predictive value of anticarbamylated protein antibodies in patients with early arthritis. Arthritis Rheum. 2015;67:2620.

Van der Heijde D, van der Helm-van Mil AHM, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis. 2013;72:479-81. doi: 10.1136/annrheumdis-2012- 202779

Rezaei H, Torp-Pedersen S, af Klint E, et al. Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis – a probabilistic approach. Arthritis Res Ther. 2014;16:448. doi: 10.1186/s13075-014-0448-6

Sahbudin I, Pickup L, Cader Z, et al. Ultrasound-defined tenosynovitis is a strong predictor of early rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):69-70. doi: 10.1136/annrheumdis-2015-eular.1591

Nieuwenhuis WP, Krabben A, Stomp W, et al. Evaluation of magnetic resonance imaging-detected tenosynovitis in the hand and wrist in early arthritis. Arthritis Rheum. 2015;67:869-76. doi: 10.1002/art.39000

Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70:1292-5. doi: 10.1136/ard.2010.142729

Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis. 2013;72:858-62. doi: 10.1136/annrheumdis-2012-201456

Lukas C, Combe B, Ravaud P, et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Etude et Suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum. 2011;63:1804-11. doi: 10.1002/art.30371

Sö derlin MK, Bergman S; BARFOT Study Group. Absent «Window of Opportunity» in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis. J Rheumatol. 2011;38:2160-8. doi: 10.3899/jrheum.100991

Van Nies JAB, Tsonaka R, Gaujoux-Viala C, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74:806-12. doi: 10.1136/annrheumdis-2014- 206047

Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68:1-26. doi: 10.1002/art.39480

Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):8-26 (In Russ.)]. doi: 10.14412/1995- 4484-2014-8-26

Verschueren P, de Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74:27-34. doi: 10.1136/annrheumdis-2014-205489

Den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy («COBRA-light») compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. 2014;73:1071-8. doi: 10.1136/annrheumdis- 2012-202818

De Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73:1331-9. doi: 10.1136/annrheumdis-2013-204788

Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824-35. doi: 10.1002/art.34498

Daien CI, Hua C, Combe B, Landewe R. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open. 2017;3(1):e000404. doi: 10.1136/rmdopen-2016- 000404

Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53:421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995- 4484-2015-421-433

Duran J, Bockorny M, Dalasl D, et al. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systemic review. Ann Rheum Dis. 2016;75:1595-8. doi: 10.1136/annrheumdis-2016-209383

Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377-86. doi: 10.1056/NEJMoa1310476

Fleischmann R, Schiff M, van der Heijde D. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheum. 2016 Oct 9. doi: 10.1002/art.39953

Emery P, Bingham C, Burmester GR. The first study of certolizumab pegol in combination with methotrexate in DMARDnaive early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the C-EARLY randomized, double-blind, controlled phase 3 study. Ann Rheum Dis. 2015;74(Suppl 2):712. doi: 10.1136/annrheumdis-2015-eular.1493

Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75:1081-91. doi: 10.1136/annrheumdis-2015-207628

Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844-50. doi: 10.1136/annrheumdis-2012-201612

Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. 2014;73:536-43. doi: 10.1136/annrheumdis-2012-202433

Atsumi T, Yamamoto K, Takeuchi T, et al. The first early rheumatoid arthritis, certolizumab pegol, multicenter, double-blind, randomized, parallel-group study: C-Opera, in patients fulfilling the 2010 ACR/EULAR classification criteria, demonstrates inhibition of joint damage progression. Ann Rheum Dis. 2014;73:484. doi: 10.1136/annrheumdis-2014-eular.1448 (FRI0278)

Bijlsma JW, Welsing PM, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016 Jul 23;388(10042):343-55. doi: 10.1016/S0140-6736(16)30363-4

Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19-26. doi: 10.1136/annrheumdis-2014-206106

Horslev-Petersen K, Hetland ML, Ornbjerg LM, et al. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, doubleblinded, randomised, controlled trial (OPERA). Ann Rheum Dis. 2016;75:1645-53. doi: 10.1136/annrheumdis-2015-208166

Horslev-Petersen K, Hetland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intraarticular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallelgroup, placebo-controlled trial. Ann Rheum Dis. 2014;73:654-61. doi: 10.1136/annrheumdis-2012-202735

Atsumi T, Yamamoto K, Takeuchi T. Clinical benefit of 1-year certolizumab pegol treatment in mtx-naive, early rheumatoid arthritis patients is maintained after discontinuation up to 1 year. Arthritis Rheum. 2016;75:75-83. doi: 10.1136/annrheumdis-2015- 207511

Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321-32. doi: 10.1016/S0140-6736(13)61751-1

Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75-85. doi: 10.1136/annrheumdis-2013-203440

Ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis. 2015;74:1233-40. doi: 10.1136/annrheumdis-2013-205143

Hazlewood GS, Barnabe C, Tomilison G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systemic review and network meta-analysis. BMJ. 2016;353:i1777. doi: 10.1136/bmj.i1777

Fleischmann R, Tongbram V, van Vollenhoven R, et al. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open. 2017;3(1):e000371. doi: 10.1136/rmdopen-2016-000371

Mazouyes A, Clay M, Bernard AC, et al. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials. Joint Bone Spain. 2016 Dec 15. pii: S1297-319X(16)30208-1. doi: 10.1016/j.jbspin.2016.10.010

Charles-Schoeman C, Wang X, Lee YY, et al. Association of triple therapy with improvement in cholesterol profiles over two-year followup in the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2016;68(3):577-86. doi: 10.1002/art.39502

Charles-Schoeman C, Yin Lee Y, Shahbazian A, et al. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheum. 2017;69(1):46-57. doi: 10.1002/art.39833

Sharma TS, Wasko MC, Tang X, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016;5(1). pii: e002867. doi: 10.1161/JAHA.115.002867

Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65 [Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-65 (In Russ.)]. doi: 10.14412/1995-4484-2016- 247-265

Verschueren P, de Cock D, Corluy L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015;17:97. doi: 10.1186/s13075-015-0611-8

Seegobin SD, Ma MHY, Dahanayake C, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther. 2014;16:R13. doi: 10.1186/ar4439

Dixon WG, Abrahamowicz M, Beauchamp M-E, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71:1128- 33. doi: 10.1136/annrheumdis-2011-200702

Del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2014;66:264-72. doi: 10.1002/art.38210

Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74:415-21. doi: 10.1136/annrheumdis-2013-204021

Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal antiinflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-9. doi: 10.1136/annrheumdis-2014-206624

Ajeganova S, Svensson B, Hafström I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4:e004259. doi: 10.1136/bmjopen-2013- 004259

Bijlsma JWJ, Buttgereit F. Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies. Rheumatology (Oxford). 2016;55 Suppl 2:ii3-ii5. doi: 10.1093/rheumatology/kew344

Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013) – место глюкокортикоидов. Научно-практическая ревматология. 2015;53:238-50 [Nasonov EL. New guidelines for the management of rheumatoid arthritis (EULAR, 2013): The place of glucocorticoids. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;53(3):238-50 (In Russ.)]. doi: 10.14412/1995-4484-2015-238-250

Palmowski Y, Buttgereit T, Dejaco C, et al. The "official view" on glucocorticoids in rheumatoid arthritis. A systematic review of international guidelines and consensus statements. Arthritis Care Res (Hoboken). 2016 Dec 28. doi: 10.1002/acr.23185 91. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952-7. doi: 10.1136/annrheumdis-2015-208916

Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. doi: 10.1136/ard.2009.123919

Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis- 2015-208337

Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6-16. doi: 10.1136/annrheumdis-2013-203419

Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2016 Sep 22. pii: annrheumdis-2016-209467. doi: 10.1136/annrheumdis-2016- 209467

Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139

Combe B, Logeart I, Belkacemi MC, et al. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis. 2015;74:724-9. doi: 10.1136/annrheumdis-2013-204178

Ruyssen-Witrand A, Guernec G, Nigon D, et al. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. Ann Rheum Dis. 2015;74:1676-83. doi: 10.1136/annrheumdis-2013-204906

Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16:R56. doi: 10.1186/ar4491

Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404-13. doi: 10.1136/ard.2011.149765

100

Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, et al. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev. 2009;(4):CD006853. doi: 10.1002/14651858.CD006853.pub2

101

Ekelman BA, Hooker L, Davis A, et al. Occupational therapy interventions for adults with rheumatoid arthritis: an appraisal of the evidence. Occup Ther Health Care. 2014;28:347-61. doi: 10.3109/07380577.2014.919687

102

Manning VL, Hurley MV, Scott DL, et al. Education, self-management, and upper extremity exercise training in people with rheumatoid arthritis: a randomized controlled trial. Arthritis Care Res. 2014;66:217-27. doi: 10.1002/acr.22102

103

Mathieux R, Marotte H, Battistini L, et al. Early occupational therapy programme increases hand grip strength at 3 months: results from a randomised, blind, controlled study in early rheumatoid arthritis. Ann Rheum Dis. 2009;68:400-3. doi: 10.1136/ard.2008.094532

104

Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73:62-8. doi: 10.1136/annrheumdis-2013-204223

105

Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016;75:965-73. doi: 10.1136/annrheumdis-2016-209233

106

Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31. doi: 10.1136/ard.2009.113696

107

Gherghe AM, Dougados M, Combe B, et al. Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD Open 2015;1:e000128. doi: 10.1136/rmdopen- 2015-000128

108

Daien CI, Sellam J. Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response. RMD Open. 2015;1:e000012. doi: 10.1136/rmdopen-2014-000012

109

Bacconnier L, Rincheval N, Flipo R-M, et al. Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. Rheumatology. 2015;54:520-7. doi: 10.1093/rheumatology/keu371

110

Radner H, Yoshida K, Mjaavatten MD, et al. Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum. 2015;45:167-73. doi: 10.1016/j.semarthrit.2015.06.010

111

Heimans L, van den Broek M, le Cessie S, et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res. 2013;65:1235-42. doi: 10.1002/acr.21978

112

Sandberg MEC, Bengtsson C, Kä llberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2014;73:2029-33. doi: 10.1136/annrheumdis-2013-205094

113

Wevers-de Boer K, Visser K, Heimans L, et al. Extended report: remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis. 2012;71:1472-7. doi: 10.1136/annrheumdis-2011-200736

114

Mirpourian M, Salesi M, Abdolahi H, et al. The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis. J Res Med Sci Off J Isfahan Univ Med Sci. 2014;19:509-14.

115

Saevarsdottir S, Rezaei H, Geborek P, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2015;74:1509-14. doi: 10.1136/annrheumdis-2013-204601

116

Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011;63:26-36. doi: 10.1002/art.27758

117

Rojas-Serrano J, Perez LL, Garcia CG, et al. Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. Clin Rheumatol. 2011;30:1589-93. doi: 10.1007/s10067-011-1775-5

118

Wessels JAM, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007;56:1765-75. doi: 10.1002/art.22640

119

Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74:954-62. doi: 10.1136/annrheumdis-2014- 206807

120

Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULARendorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350

121

Mankia K, Emery P. Preclinical rheumatoid arthritis: progress toward prevention. Arthritis Rheum. 2016;68(4):779-88. doi: 10.1002/art.39603

122

Mankia K, Emery P. A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals. Curr Opin Rheumatol. 2016;28(3):260-6. doi: 10.1097/BOR.0000000000000268

123

Deane KD, Striebich CC, Holers VM. Prevention of rheumatoid arthritis: Now is the time, but how to proceed? Arthritis Rheum. 2017 Feb 19. doi: 10.1002/art.40061

124

Gerlag DM, Norris JM, Tak PP. Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology (Oxford). 2016;55(4):607-14. doi: 10.1093/rheumatology/kev347

125

Bos WH, Dijkmans BA, Boers M, et al. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69(3):571-4. doi: 10.1136/ard.2008.105767

126

Saleem B, Mackie S, Quinn M, et al. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? Ann Rheum Dis. 2008;67(8):1178-80. doi: 10.1136/ard.2007.084269

127

Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2011;70(8):1519.

128

Machold KP, Landewe R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis. 2010;69(3):495-502. doi: 10.1136/ard.2009.122473

129

Verstappen SM, McCoy MJ, Roberts C, et al; STIVEA investigators. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis. 2010;69(3):503-9. doi: 10.1136/ard.2009.119149

130

Van Aken J, Heimans L, Gillet-van Dongen H, et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis. 2014;73(2):396-400. doi: 10.1136/annrheumdis-2012-202967

131

Burgers LE, Allaart CF, Huizinga TW, et al. Clinical trials aiming to prevent Rheumatoid Arthritis cannot detect prevention without adequate risk stratification; the PROMPT-trial as example. Arthritis Rheum. 2017 Feb 19. doi: 10.1002/art.40062

132

Gerlag D, Safy M, Maijer K, et al. Prevention of rheumatoid arthritis by B cell directed therapy in earliest phase of the disease: the PRAIRI stude. Ann Rheum Dis. 2016;75(Suppl 2):125[OP0182]. doi: 10.1136/annrheumdis-2016-eular.6042

133

Van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56(5):1424-32. doi: 10.1002/art.22525

134

Van Aken J, van Dongen H, le Cessie S, et al. Long-term outcome of rheumatoid arthritis that presented with undifferentiated arthritis compared to rheumatoid arthritis at presentation: an observational cohort study. Ann Rheum Dis. 2006;65:20-5. doi: 10.1136/ard.2005.038471

135

Van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007;56(2):433-40. doi: 10.1002/art.22380

136

Van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recentonset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008;58(8):2241-7. doi: 10.1002/art.23681

137

Van Steenbergen HW, Mangnus L, Reijnierse M, et al. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis. 2016;75(10):1824- 30. doi: 10.1136/annrheumdis-2015-208138

138

Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69(3):490-4. doi: 10.1136/ard.2008.105759

The authors declare that there are no conflicts of interest present.